drugset / Trial / NCT03566134

A Therapeutic Exploratory Clinical Study of DA-8010 in Patients With Overactive Bladder

NCT03566134

Phase 2 Completed 306 enrolled Dong-A ST Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

A Therapeutic Exploratory Clinical Study to evaluate the efficacy and safety of DA-8010 in Patients with Overactive Bladder and to determine the optimal dose of DA-8010

Timeline

Start
2018-07-10
Primary completion
2019-12-27
Completion
2019-12-27

Drugs

EvaluationDrugModalityDoseRoute
Comparator Solifenacin Small molecule 5 mg Oral
Subject VELUFENACIN Small molecule 2.5 mg Oral
Subject VELUFENACIN Small molecule 5 mg Oral

Indications